To study the utility of pten marker in endometrial Hyperplasia without atypia- one year prospective and Retrospective observational study

Abstract

BACKGROUND: Endometrial hyperplasia (EH) is an irregular proliferation of endometrial glands. EH is involved in the development of endometrial cancer (EC) of endometrioid type, which is the most common gynecologic malignancy in the Western World. The tumor suppressor protein phosphatase and tensin homolog (PTEN) has probably been the most studied marker, as it is most commonly mutated in endometrial carcinogenesis.The tumor suppressor gene PTEN was identified on chromosome 10p23.31. It encodes a 403- amino acid PTEN protein (47kDa) with the activity of phosphatase that can act on both polypeptide and phosphoinositide substrates(9-12). Loss of PTEN is demonstrated by immunohistochemical staining . This research was undertaken to study expression of PTEN in Endometrial hyperplasia without atypia cases. OBJECTIVE: To study prognostic value of immunohistochemical assessment of PTEN expression in Endometrial hyperplasia without atypia.